Infinity Group’s Tianyi Medical Fund Leads 250 Million RMB Investment in Asymchem Laboratories (Tianjin) Co., Ltd.

TIANJIN, China, August 17, 2011 -

Tianyi Medical Private Equity Fund announced today that it has led a 250 million RMB investment round in Asymchem Laboratories (Tianjin) Co., Ltd. (Asymchem).  Tianyi Medical Private Equity Fund, a joint venture of Infinity Group and Tianjin Venture Capital (TJVC), focuses on investments in the biomedical industry. Tianyi Medical Private Equity Fund and TJVC co-invested 90 million RMB.

Asymchem is an international pharmaceutical company which provides professional biotechnology services to help pharmaceutical companies to shorten the development period of new products and speed up the launching of new drugs. The main business of Asymchem is to develop, optimize, and manufacture raw materials, API as well as to prepare products according to cGMP requirements, and to provide clinical research medicines and marketed medicine according to US and EU standards. Asymchem has established five companies and is the biggest pharmaceutical company providing CMO services in China.

The investment announced today will be used to help Asymchem increase its production capability, undertake more orders from international pharmaceutical companies, improve Asymchem’s general competitive capabilities, strengthen the merger of the Chinese and international markets, and promote the interconnection of the pharmaceutical industry in China with that of the international pharmaceutical industry.

“Asymchem is one of the largest and most respected pharmaceutical manufactures in China and a ‘one stop shop’ and strategic partner for several multi-national pharmaceutical companies. Under the impressive leadership of Chairman and CEO Dr. Hao Hong and his very professional management team, the company has continuously shown steady growth in revenues, even in challenging times and a competitive arena.  We are very happy to invest in Asymchem as we see a bright future for this company,” said Dr. Bella Ohana, Managing Director of Life Science at Infinity Group.

About Infinity Group

Infinity Group is an RMB fund pioneer and the leader in cross border China, RMB and dollar private equity platforms and technology cooperation. It is also the founder of the Infinity IP Bank, the hub for IP development and commercialization in China. Infinity Group currently manages twelve funds, ten in China. Infinity has a portfolio of 45 companies and has made 22 successful exits. Infinity, which has the greatest number of RMB funds in China, was founded by the China Development Bank and IDB Group (the largest conglomerate in Israel).  Infinity serves as a bridge for Chinese companies that want to integrate technology and know-how to become industry leaders domestically as well as to compete internationally, and for non-Chinese companies, with proven technology, seeking to capitalize on the Chinese market. Sectors of focus include: medical device, pharma and healthcare services, information technology, agritech, materials, as well as water and clean technology and energy. Recent high profile activities include the technology acquisitions from Israeli companies Pulsar and Ghost, investments in Haolianluo (Beijing, China), United Water Corporation (Shanghai, China) and Weigo (Shangdong, China), as well as exits from Tegrity, Orsus, FuturaGene and Teledata Networks. Other China-related exits include Shellcase, Nanomotion, and a partial exit from Digital China. Infinity currently has offices in Beijing, Changzhou, Chengdu, Harbin, Hong Kong, Jining, New York, Ningbo, Shanghai, Shijiazhuang, Suzhou, Tel Aviv and Tianjin.

For more information, please visit www.infinity-equity.com or please contact Marjie Hadad at marjie.hadad@infinity-equity.com or call +972-54-536-5220. For Chinese language inquiries, please contact Joey Zhu at joey.zhu@infinity-equity.com  or at 008613601212411.

.